Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

PUBLICATION DATE

8 results
Display

A Case Report of Cyanopsia after Taking Sildenafil

Lee CH, Yoon JS, Ji E

The emergence of phosphodiesterase (PDE) 5 inhibitors gave rise to the solution for erectile dysfunction, starting with the development of sildenafil. Although their efficacy in treating erectile dysfunction has been...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
A Comparative Study on the Clinical Efficacy and Safety between Combination Therapy with CDK 4/6 Inhibitor and AI Versus AI Monotherapy in HR+/HER type2- Advanced Breast Cancer: Updated Meta-analysis

Kim MJ, Kim K, Cho M, Sohn K, Baek Ih

Objective: The aim of the study was to perform a meta-analysis of randomized clinical trials to compare the clinical efficacy and safety between combination of cyclin-dependent kinase (CDK) 4/6 inhibitors...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Efficacy and Safety of Nivolumab and Pembrolizumab in Elderly Cancer Patients

Kim HS, Jeong H, Shim MK

Background: Nivolumab and pembrolizumab are antagonists of the programmed death-ligand 1 (PD-L1) receptor that function as immuno-oncological agents. This study aimed to evaluate the safety and efficacy of nivolumab and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Potential Drug-Drug Interactions in Patients Taking HMG CoA-reductase Inhibitors

Lee KJ, Kim KR, Seong JM, Ryu SW, Lee HY, Cho S, Cheong Y, Nam KN, Lee YJ

Objective: The 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) are frequently prescribed medications worldwide for the treatment of hypercholesterolemia. Statins are considered to be well tolerated; however, they have a potential...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Evaluation of Information Consistency of Clinically Significant Drug Interactions in Tyrosine Kinase Inhibitors

An S, Lee JY, Ah YM

Background: Drug-drug interactions (DDIs) in patients using oral anticancer treatment are more common than in those using injectable anticancer agents. In addition, DDIs related to anticancer treatment are known to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The Effects of Intrapatient Variability in Tacrolimus Concentration on Clinical Outcomes Immediately After Liver Transplantation

Kim E, Kim B, Cho J, Lee JH, Lee E, Yu YM, Cho JY, Lee E, Choi Y

Background: Tacrolimus, a calcineurin inhibitor, is an immunosuppressant used in post-transplantation maintenance therapy. The drug has a narrow therapeutic range and requires periodic therapeutic drug monitoring. Although many studies have...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Management of Osteoporosis in Liver Transplant Recipients

Choi H, Kim B, Kim Y, Lee J, Lee E, Lee E, Cho JY, Choi Y

Background: Prevention of osteoporosis and bone fracture is one of the important issues for liver transplant recipients because a long history of liver disease and lifelong use of immunosuppressants, including...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Patterns of Spontaneous Adverse Events Reporting on Human Papillomavirus Vaccines according to the Applicability of Brighton Collaboration Criteria in Korea from 2008 to 2017

Kim MS, You SH, Park HM, Lee MT, Kang YJ, Koo H, Jung SY

Objective: To describe patterns of spontaneous reporting on adverse events following immunization (AEFIs) using the human papilloma virus (HPV) vaccine according to the Brighton Collaboration (BC) criteria. Methods: We used...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2021 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr